HEALTH NOTES:Ā Antibiotics 'help treat depression'
HEALTH NOTES: Doctors in South London recruited 39 patients suffering 'treatment-resistant' depression and gave half of them the antibiotic minocycline. (Source: the Mail online | Health)
Source: the Mail online | Health - January 30, 2021 Category: Consumer Health News Source Type: news
Antibiotic may improve outcomes for depression in people with low level inflammation
(NIHR Maudsley Biomedical Research Centre) King's College London researchers have found evidence that minocycline, a widely used antibiotic with anti-inflammatory properties, gave greater improvement in depressive symptoms in patients with treatment resistant depression with low-grade peripheral inflammation. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 27, 2021 Category: International Medicine & Public Health Source Type: news
Minolira (Minocycline Hydrochloride Extended-Release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 14, 2021 Category: Drugs & Pharmacology Source Type: news
Expanding Treatment Options for Rosacea Expanding Treatment Options for Rosacea
A new study reports on the beneficial effects of topical minocycline on papulopustular rosacea.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Amzeeq (Minocycline Topical Foam) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 14, 2020 Category: Drugs & Pharmacology Source Type: news
Zilxi (Minocycline Topical Foam) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves Zilxi (minocycline) Topical Foam for the Treatment of Rosacea
BRIDGEWATER, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the“Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 29, 2020 Category: Drugs & Pharmacology Source Type: news
Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT
Minocycline is an anti-inflammatory drug and protects against the toxic effects of Ī²-amyloid in vitro and in animal models of Alzheimer ' s disease. To the best of our knowledge, no randomised placebo-controlled clinical trials in patients with Alzheimer ' s disease looking at the efficacy and tolerability of minocycline have been carried out. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 28, 2020 Category: Consumer Health News Source Type: news
Minocycline Foam Promising Against Rosacea Minocycline Foam Promising Against Rosacea
The new topical minocycline 1.5% foam FMX103 from Foamix Pharmaceuticals appears effective against moderate-to-severe papulopustular rosacea, according to two randomized trials.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 12, 2020 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Two More Alzheimer's Drug Candidates Fail Two More Alzheimer's Drug Candidates Fail
The BACE inhibitor lanabecestat and the antibiotic minocycline failed to slow cognitive decline in randomized controlled trials.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 9, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
How Is Hidradenitis Suppurativa Treated?
Discussion
Hidradenitis suppurativa (HS) is a recurrent, chronic inflammatory disease of the hair follicles particularly in the apocrine gland-bearing areas of the axilla, inguinal, perianal, mammary and inframammary areas. Onset is usually after puberty, in the early 20s. It is more common in females than males. Prevalence is estimated to be 0.05- 4.1%. It can be associated with premature adrenarche, metabolic syndrome and obesity.
The lesions are often pruritic, painful, and with malodorous purulent drainage. It often begins with comedomes and tender nodules, and can easily progress to painful abscesses with purulent f...
Source: PediatricEducation.org - November 25, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Amzeeq (Minocycline Topical Foam) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2019 Category: Drugs & Pharmacology Source Type: news
First Topical Form of Minocycline for Acne
FDA Clears First Topical Form of Minocycline for Acne (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 22, 2019 Category: General Medicine Source Type: news
FDA Clears First Topical Form of Minocycline for Acne FDA Clears First Topical Form of Minocycline for Acne
Minocycline topical foam (Amzeeq) is for the treatment of inflammatory lesions of nonnodular moderate to severe acne vulgaris in adults and children aged 9 years or older.FDA Approvals (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - October 21, 2019 Category: Primary Care Tags: Dermatology News Alert Source Type: news
FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the“Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 18, 2019 Category: Drugs & Pharmacology Source Type: news
